Highlighting Immunotherapy Clinical Trials

Clinical Trials e-Newsletter | November 2019

Clinical Trials e-Newsletter

About Immunotherapy Treatments

I mmunotherapies are being successfully used for the treatment of a wide variety of cancers, including prostate cancer. Their success has improved the long-term outlook for cancer patients, especially those with advanced cancers. In contrast to conventional cancer therapies, immunotherapies focus on enhancing the patient's immune system response to the cancer. This e-newsletter highlights some exciting ongoing immunotherapy clinical trials for prostate cancer with updates on other trials that are part of PHEN's clinical trials rally.

A clinical trial could be your best treatment option.

Immunotherapy Clinical Trials

This month’s clinical trials focus is on the immunotherapy investigational drug, Pembrolizumab , which is used in combination with other therapies, anti-DNA repair ( olaparib ), hormonal ( enzalutamide ), or a chemotherapy ( docetaxel ) therapies. Each of the clinical trials are for patients with metastatic castrate resistant prostate cancer (mCRPC).

KEYLYNK 7339

Pembrolizumab in combination with olaparib (anti-DNA)

Patient Summary

KEYNOTE 921

Pembrolizumab in combination with enzalutamide (hormonal)

Patient Summary

KEYNOTE 641

Pembrolizumab in combination with docetaxel (chemotherapy)

Patient Summary

Updates on Clinical Trials

PROVENT Clinical Trial

Dendreon Pharmaceuticals has completed patient enrollment ahead of schedule in an ongoing Phase 3 trial assessing the safety and efficacy of its immunotherapy Provenge

( sipuleucel-T ) for men with early-stage prostate cancer on active surveillance, the company announced.

Read Full Story

Janssen Announces US FDA Breakthrough Therapy

PHEN Clinical Trials Rally trial, Galahad, receives fast review and development approval from the FDA for the treatment of mCRPC patients with BRCA1/2 mutations.

Read Full Story

Find Your Trial (FYT) Tool

Find A Trial That Fits

Your Needs

Click on the link below that defines where you are on your prostate cancer journey and PHEN's "Find Your Trial (FYT) Tool" will present you with a listing of available clinical trials.

Patients with Low and Intermediate Risk Prostate Cancer

High Risk Prostate Cancer Patients

Patients Treated with Prostatectomy or Radiation

Patients with Recurrent Prostate Cancer

Patients with Castration Resistant Prostate Cancer (CRPC)

Metastatic Castration Resistant Prostate Cancer (mCRPC) Patients

Understanding Castration Resistant Prostate Cancer

Androgen deprivation (hormone) therapy, such as Lupron, works to reduce testosterone in the body to castration levels to prevent or slow the progression of prostate cancer.

What is Castration resistant Prostate Cancer?

Prostate cancer becomes Castration Resistant when the cancer progresses despite treatment with anti-androgen therapy.

What is non-Metastatic Castration Resistant Prostate Cancer?

Castration Resistant Prostate Cancer where no metastases have been detected.

What is Metastatic Castration Resistant Prostate Cancer?

Castration Resistant Prostate Cancer that has spread and metastasized to other parts of the body such as bones and other organs.